[go: up one dir, main page]

PT3071570T - 2,6-SUBSTITUTED PURINE DERIVATIVES AND ITS USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS - Google Patents

2,6-SUBSTITUTED PURINE DERIVATIVES AND ITS USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS

Info

Publication number
PT3071570T
PT3071570T PT148064470T PT14806447T PT3071570T PT 3071570 T PT3071570 T PT 3071570T PT 148064470 T PT148064470 T PT 148064470T PT 14806447 T PT14806447 T PT 14806447T PT 3071570 T PT3071570 T PT 3071570T
Authority
PT
Portugal
Prior art keywords
treatment
proliferative disorders
purine derivatives
substituted purine
substituted
Prior art date
Application number
PT148064470T
Other languages
Portuguese (pt)
Inventor
Carl BEHENNA Douglas
Cheng Hengmiao
Cho-Schultz Sujin
Otto Johnson Theodore Jr
Charles Kath John
Nagata Asako
Krishnan Nair Sajiv
Paul Planken Simon
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PT3071570T publication Critical patent/PT3071570T/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT148064470T 2013-11-21 2014-11-10 2,6-SUBSTITUTED PURINE DERIVATIVES AND ITS USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS PT3071570T (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361907322P 2013-11-21 2013-11-21

Publications (1)

Publication Number Publication Date
PT3071570T true PT3071570T (en) 2018-08-01

Family

ID=52004011

Family Applications (1)

Application Number Title Priority Date Filing Date
PT148064470T PT3071570T (en) 2013-11-21 2014-11-10 2,6-SUBSTITUTED PURINE DERIVATIVES AND ITS USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS

Country Status (39)

Country Link
US (1) US9290496B2 (en)
EP (1) EP3071570B1 (en)
JP (2) JP6166845B2 (en)
KR (1) KR101919672B1 (en)
CN (1) CN105916853B (en)
AP (1) AP2016009219A0 (en)
AR (1) AR098492A1 (en)
AU (1) AU2014351433B2 (en)
CA (1) CA2931034C (en)
CL (1) CL2016001151A1 (en)
CR (1) CR20160236A (en)
CU (1) CU24402B1 (en)
CY (1) CY1120478T1 (en)
DK (1) DK3071570T3 (en)
DO (1) DOP2016000115A (en)
EA (1) EA029842B1 (en)
ES (1) ES2681799T3 (en)
GE (2) GEP20186878B (en)
GT (1) GT201600091A (en)
HR (1) HRP20181036T1 (en)
HU (1) HUE039858T2 (en)
IL (1) IL245698B (en)
LT (1) LT3071570T (en)
MA (1) MA39043B1 (en)
MD (1) MD20160053A2 (en)
MX (1) MX2016006397A (en)
MY (1) MY184433A (en)
NI (1) NI201600072A (en)
PE (1) PE20160885A1 (en)
PH (1) PH12016500911A1 (en)
PL (1) PL3071570T3 (en)
PT (1) PT3071570T (en)
RS (1) RS57537B1 (en)
SI (1) SI3071570T1 (en)
TN (1) TN2016000188A1 (en)
TW (1) TWI538913B (en)
UA (1) UA115388C2 (en)
UY (1) UY35845A (en)
WO (1) WO2015075598A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
WO2015039612A1 (en) 2013-09-18 2015-03-26 北京韩美药品有限公司 Compound inhibiting kinase activities of btk and/or jak3
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
US20180201614A1 (en) * 2015-05-12 2018-07-19 Kalyra Pharmaceuticals, Inc. Bicyclic compounds
EP3518925A4 (en) * 2016-09-30 2020-04-15 SRI International DUAL CLK / CDK1 INHIBITORS FOR THE TREATMENT OF CANCER
US20190275049A1 (en) 2016-11-16 2019-09-12 Pfizer Inc. Combination of an EGFR T790M Inhibitor and a CDK Inhibitor for the Treatment of Non-Small Cell Lung Cancer
JP2020505327A (en) 2016-12-23 2020-02-20 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． EGFR proteolytic targeting chimeric molecules and related methods of use
WO2018163066A1 (en) 2017-03-10 2018-09-13 Pfizer Inc. Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors
EP3592740B1 (en) 2017-03-10 2022-02-09 Pfizer Inc. Cyclic substituted imidazo[4,5-c]quinoline derivatives
US12012408B2 (en) 2018-06-22 2024-06-18 The Royal Institution For The Advancement Of Learning/Mcgill University Purine compounds and method for the treatment of cancer
KR20200105631A (en) * 2019-02-28 2020-09-08 보로노이바이오 주식회사 Heteroaryl comprising N derivatives and pharmaceutical composition containing the same as an active ingredient
KR102841446B1 (en) * 2020-05-20 2025-07-31 티와이케이 메디슨즈, 인코포레이티드 Compounds used as RET kinase inhibitors and uses thereof
CN117940420A (en) 2021-09-14 2024-04-26 勃林格殷格翰国际有限公司 3-Phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives and their use as pharmaceuticals

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
SG64322A1 (en) 1991-05-10 1999-04-27 Rhone Poulenc Rorer Int Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
FI941572L (en) 1991-10-07 1994-05-27 Oncologix Inc Combination and method of use of anti-erbB-2 monoclonal antibodies
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
ATE503496T1 (en) 1992-02-06 2011-04-15 Novartis Vaccines & Diagnostic BIOSYNTHETIC BINDING PROTEIN FOR TUMOR MARKERS
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
US5861510A (en) 1995-04-20 1999-01-19 Pfizer Inc Arylsulfonyl hydroxamic acid derivatives as MMP and TNF inhibitors
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE69624081T2 (en) 1995-12-20 2003-06-12 Agouron Pharmaceuticals, Inc. Matrix metalloprotease inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
ES2169355T3 (en) 1996-03-05 2002-07-01 Astrazeneca Ab DERIVATIVES OF 4-ANILINOQUINAZOLINA.
EP0912559B1 (en) 1996-07-13 2002-11-06 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
ES2191187T3 (en) 1996-07-13 2003-09-01 Glaxo Group Ltd BICYCLE HETEROAROMATIC COMPOUNDS AS INHIBITORS OF PROTEIN TIROSIN-QUINASA.
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
EA199900036A1 (en) 1996-07-18 1999-06-24 Пфайзер Инк METALLIC PROTEASIS INHIBITORS OF MATRIX ON THE BASIS OF PHOSPHINATES, PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT
US5866702A (en) 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
US6790958B2 (en) 1996-08-02 2004-09-14 Robert T. Lum Purine inhibitors of cyclin dependent kinase 2 & IKBA
US6794390B2 (en) 1996-08-02 2004-09-21 Cv Therapeutics, Inc. Purine inhibitors of cyclin dependent kinase 2 & ikappabalpha
PL331895A1 (en) 1996-08-23 1999-08-16 Pfizer Arylosulphonylamino derivatives of hydroxamic acid
DK0950059T3 (en) 1997-01-06 2004-11-01 Pfizer Cyclic sulfone derivatives
ATE248812T1 (en) 1997-02-03 2003-09-15 Pfizer Prod Inc ARYLSULFONYLHYDROXAMIC ACID DERIVATIVES
JP2000507975A (en) 1997-02-07 2000-06-27 ファイザー・インク N-hydroxy-β-sulfonylpropionamide derivatives and their use as matrix metalloproteinase inhibitors
PL334997A1 (en) 1997-02-11 2000-03-27 Pfizer Derivatives or arylosulphonyl-hydroxamic acid
EP0984930B1 (en) 1997-05-07 2005-04-06 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
WO1998054093A1 (en) 1997-05-30 1998-12-03 Merck & Co., Inc. Novel angiogenesis inhibitors
US6255485B1 (en) 1997-08-07 2001-07-03 The Regents Of The University Of California Purine inhibitors of protein kinases, G proteins and polymerases
US6294532B1 (en) 1997-08-22 2001-09-25 Zeneca Limited Oxindolylquinazoline derivatives as angiogenesis inhibitors
EP1017682A4 (en) 1997-09-26 2000-11-08 Merck & Co Inc NEW ANGIOGENESIS INHIBITORS
CN1280580A (en) 1997-11-11 2001-01-17 辉瑞产品公司 Thienopyrimidines and thienopyridine derivatives useful as anticancer agents
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
RS49779B (en) 1998-01-12 2008-06-05 Glaxo Group Limited, BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
PA8469501A1 (en) 1998-04-10 2000-09-29 Pfizer Prod Inc HYDROXAMIDES OF THE ACID (4-ARILSULFONILAMINO) -TETRAHIDROPIRAN-4-CARBOXILICO
PA8469401A1 (en) 1998-04-10 2000-05-24 Pfizer Prod Inc BICYCLE DERIVATIVES OF HYDROXAMIC ACID
HUP0103617A2 (en) 1998-05-29 2002-02-28 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors, pharmaceutical compositions containing the compounds and their use
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (en) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク Heteroaromatic bicyclic derivatives useful as anticancer agents
JP4044839B2 (en) 2000-06-22 2008-02-06 ファイザー・プロダクツ・インク Substituted bicyclic derivatives for treating abnormal cell proliferation
ES2242771T5 (en) 2000-09-15 2011-10-14 Vertex Pharmaceuticals Incorporated PIRAZOL COMPOUNDS USEFUL AS PROTEIN QUINASE INHIBITORS.
AR042586A1 (en) 2001-02-15 2005-06-29 Sugen Inc 3- (4-AMIDOPIRROL-2-ILMETILIDEN) -2-INDOLINONE AS INHIBITORS OF PROTEIN KINASE; YOUR PHARMACEUTICAL COMPOSITIONS; A METHOD FOR THE MODULATION OF THE CATALYTIC ACTIVITY OF PROTEINQUINASE; A METHOD TO TREAT OR PREVENT AN AFFECTION RELATED TO PROTEINQUINASE
WO2002072549A1 (en) 2001-03-12 2002-09-19 Millennium Pharmaceuticals, Inc. Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor
US20040235867A1 (en) 2001-07-24 2004-11-25 Bilodeau Mark T. Tyrosine kinase inhibitors
EP1578722A4 (en) 2001-10-12 2006-09-06 Irm Llc KINASE INHIBITOR SKELETERS AND METHODS OF PREPARING THE SAME
US20060009642A1 (en) 2001-10-12 2006-01-12 Irm Llc, A Delaware Limited Liability Company Methods for the synthesis of substituted purines
US6949644B2 (en) 2001-10-12 2005-09-27 Irm Llc Methods for the synthesis of substituted purines
WO2004041285A1 (en) 2002-10-31 2004-05-21 Amgen Inc. Antiinflammation agents
WO2005020892A2 (en) 2003-08-08 2005-03-10 Mitochroma Research, Inc. Pharmaceutical compositions and methods for metabolic modulation
US20070184067A1 (en) 2003-08-08 2007-08-09 Dusan Miljkovic Alimentary compositions and methods for metabolic modulation
MXPA06001758A (en) 2003-08-15 2006-08-11 Irm Llc 6-substituted anilino purines as rtk inhibitors.
US20060029642A1 (en) 2004-08-03 2006-02-09 Dusan Miljkovic Methods and compositions for improved chromium complexes
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
FR2876583B1 (en) 2004-10-15 2007-04-13 Centre Nat Rech Scient Cnrse USE OF PURINE DERIVATIVES FOR THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF MUCOVISCIDOSIS AND DISEASES ASSOCIATED WITH A DEFECT OF ADDRESSING PROTEINS IN CELLS
GB0502573D0 (en) 2005-02-08 2005-03-16 Topotarget As Therapeutic compounds
GB0526246D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
WO2007092496A2 (en) 2006-02-07 2007-08-16 Conforma Therapeutics Corporation 7,9-dihydro-purin-8-one and related analogs as hsp90-inhibitors
WO2007105023A1 (en) 2006-03-15 2007-09-20 Csir Modulation of phosphoryl transferase activity of glutamine synthetase
EP2076268B1 (en) 2006-10-19 2013-01-23 Genzyme Corporation Roscovitine for the treatment of certain cystic diseases
WO2008057402A2 (en) 2006-11-02 2008-05-15 Cytovia, Inc. N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof
JP2010516774A (en) * 2007-01-26 2010-05-20 アイアールエム・リミテッド・ライアビリティ・カンパニー Purine compounds and compositions as kinase inhibitors for treating Plasmodium related diseases
US8404674B2 (en) * 2007-03-07 2013-03-26 Boehringer Ingelheim International Gmbh Substituted 9H-purin-2-YL compounds, compositions thereof and uses thereof
WO2009023179A2 (en) 2007-08-10 2009-02-19 Genelabs Technologies, Inc. Nitrogen containing bicyclic chemical entities for treating viral infections
KR20100068286A (en) 2007-10-17 2010-06-22 노파르티스 아게 Purine derivatives as adenosine a1 receptor ligands
US9089572B2 (en) 2008-01-17 2015-07-28 California Institute Of Technology Inhibitors of p97
WO2010019392A1 (en) 2008-08-13 2010-02-18 Merck Sharp & Dohme Corp. Purine derivatives for treatment of alzheimer's disease
TW201024298A (en) * 2008-09-23 2010-07-01 Palau Pharma Sa (R)-3-(N,N-dimethylamino)pyrrolidine derivatives
PE20100362A1 (en) 2008-10-30 2010-05-27 Irm Llc PURINE DERIVATIVES THAT EXPAND HEMATOPOYETIC STEM CELLS
US8426428B2 (en) * 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
WO2010118367A2 (en) 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Antiviral pyrimidines
EP2440559B1 (en) * 2009-05-05 2018-01-10 Dana-Farber Cancer Institute, Inc. Egfr inhibitors and methods of treating disorders
FR2945747A1 (en) * 2009-05-25 2010-11-26 Centre Nat Rech Scient ANTITUMOR PHARMACEUTICAL COMPOSITION COMPRISING A CDKS INHIBITOR AND A CELL GROWTH INHIBITOR
TW201111385A (en) 2009-08-27 2011-04-01 Biocryst Pharm Inc Heterocyclic compounds as janus kinase inhibitors
US9139592B2 (en) 2010-06-14 2015-09-22 Trt Pharma Inc. Modulators of Nrf2 and uses thereof
CA2813571A1 (en) 2010-06-22 2011-12-29 University Of Central Florida Research Foundation, Inc. Substituted 2-(9h-purin-9-yl) acetic acid analogues as inhibitors of stat3
EP2627179A4 (en) * 2010-10-14 2014-04-02 Ariad Pharma Inc Methods for inhibiting cell proliferation in egfr-driven cancers
EP2635285B1 (en) * 2010-11-01 2017-05-03 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
JP5957003B2 (en) * 2010-11-10 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド Mutant selective EGFR inhibitor and use thereof
CA2832504C (en) * 2011-05-04 2019-10-01 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
US8762299B1 (en) 2011-06-27 2014-06-24 Google Inc. Customized predictive analytical model training
CA2847540C (en) * 2011-09-22 2016-05-17 Pfizer Inc. Pyrrolopyrimidine and purine derivatives
CN103159742B (en) 2011-12-16 2015-08-12 北京韩美药品有限公司 5-chloropyrimide compounds and the application as EGFR tyrosine kinase inhibitor thereof
US10799504B2 (en) 2012-01-13 2020-10-13 ACEA Therapeutics, Inc. Heterocyclic compounds and uses as anticancer agents
MX2015012106A (en) 2013-03-14 2016-01-12 Pfizer Combination of an egfr t790m inhibitor and an egfr inhibitor for the treatment of non-small cell lung cancer.
US10884952B2 (en) 2016-09-30 2021-01-05 Intel Corporation Enforcing memory operand types using protection keys

Also Published As

Publication number Publication date
MX2016006397A (en) 2016-08-01
UY35845A (en) 2015-06-30
HRP20181036T1 (en) 2018-08-24
LT3071570T (en) 2018-08-10
CR20160236A (en) 2016-07-22
AU2014351433B2 (en) 2017-08-24
JP6166845B2 (en) 2017-07-19
AR098492A1 (en) 2016-06-01
UA115388C2 (en) 2017-10-25
MY184433A (en) 2021-04-01
MD20160053A2 (en) 2016-10-31
HUE039858T2 (en) 2019-02-28
CY1120478T1 (en) 2019-07-10
EP3071570A1 (en) 2016-09-28
IL245698A0 (en) 2016-08-02
TN2016000188A1 (en) 2017-10-06
SI3071570T1 (en) 2018-12-31
PH12016500911A1 (en) 2016-06-20
DK3071570T3 (en) 2018-08-13
GT201600091A (en) 2017-11-09
KR20160077217A (en) 2016-07-01
MA39043B1 (en) 2018-09-28
TWI538913B (en) 2016-06-21
EP3071570B1 (en) 2018-06-20
PE20160885A1 (en) 2016-09-11
MA39043A1 (en) 2018-01-31
AP2016009219A0 (en) 2016-05-31
KR101919672B1 (en) 2018-11-16
US20150141402A1 (en) 2015-05-21
ES2681799T3 (en) 2018-09-17
JP2017214390A (en) 2017-12-07
CU24402B1 (en) 2019-05-03
EA201600337A1 (en) 2016-10-31
GEAP201814151A (en) 2018-03-26
WO2015075598A1 (en) 2015-05-28
CN105916853B (en) 2018-07-27
PL3071570T3 (en) 2018-10-31
AU2014351433A1 (en) 2016-06-02
CU20160073A7 (en) 2016-10-28
TW201524979A (en) 2015-07-01
CL2016001151A1 (en) 2017-01-06
EA029842B1 (en) 2018-05-31
NI201600072A (en) 2016-08-09
DOP2016000115A (en) 2016-07-15
JP2016537382A (en) 2016-12-01
US9290496B2 (en) 2016-03-22
CA2931034A1 (en) 2015-05-28
GEP20186878B (en) 2018-07-10
RS57537B1 (en) 2018-10-31
IL245698B (en) 2019-11-28
CN105916853A (en) 2016-08-31
CA2931034C (en) 2019-01-08

Similar Documents

Publication Publication Date Title
PT3071570T (en) 2,6-SUBSTITUTED PURINE DERIVATIVES AND ITS USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS
IL242610A0 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
IL283432A (en) Preparations, methods and systems for the treatment of skin disorders
IL246564A (en) 3-aryl-1-heterocyclyl-pyrazolo[3,4-d]pyrimidine derivatives and use thereof in the treatment of diseases
ZA201507155B (en) Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders
LT2970398T (en) Prefusion rsv f proteins and their use
CU20160077A7 (en) PIRROLO [2,3-D] PYRIMIDINYL, PIRROLO [2,3-B] PYRAZINYL AND PIRROLO [2,3-D] PIRIDINYL ACRYLIC
HUE044960T2 (en) Pyrrolo- [1,2, F] [1,2,4] triazines useful in the treatment of respiratory syncytial infections
DK2853289T3 (en) Device that can be implanted under the skin
LT2961410T (en) USE OF PYAZOLOPHYRIMIDINE DERIVATIVES IN THE TREATMENT OF PI3K-RELATED DISORDERS
HUE054783T2 (en) Pridopidine in the treatment of Huntington's disease
HUE037125T2 (en) Pyrrolo [3,2-D] pyrimidine derivatives for the treatment of viral infections and other diseases
HUE056006T2 (en) Combination for the treatment of Parkinson's disease
PL3004112T3 (en) Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease
PL3466425T3 (en) Use of glutarimide derivatives in the treatment of eosinophilic diseases
LT2945642T (en) FACTOR 1 PROTEIN FOR USE IN THE TREATMENT OR PREVENTION OF DISEASE
PT3004108T (en) Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease
HUE036943T2 (en) Minigastrin analogue, especially for use in CCK2 receptor positive tumor diagnostics and / or treatment
FR3004424B1 (en) REMOVABLE AIRCRAFT FOOTBOARD AND AIRCRAFT
EP2980096A4 (en) 2 ,3 ,5 -trihydroxy-androst-6-one and preparation methods and use thereof
EP2971774A4 (en) PISTON WITH REPLACEABLE AND / OR ADJUSTABLE SURFACES
GB2510477B (en) Formulations for use in the treatment of chronic fatigue and associated conditions, etc
TH1601002847A (en) 2,6-substituted purine derivatives and their use in the treatment of disorders that has increased in number more than usual
AP2015008849A0 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
TH1401006251A (en) 1H-pyrazolo[3,4-B]pyridine and its use in treating disease